Researchers use appendiceal cancer organoids to study personalized immunotherapy response

By | July 20, 2021
Wake Forest researchers and clinicians are using patient-specific tumor ‘organoid’ models as a preclinical companion platform to better evaluate immunotherapy treatment for appendiceal cancer, one of the rarest cancers affecting only 1 in 100,000 people.